Podcast about the new discovery from Nanogeios for Natural H2 amplification and production

IRIS-X distinguishes itself through the integration of nanomaterials, advanced sensors, and AI to achieve unprecedented precision in natural hydrogen and helium exploration. It drastically reduces operational costs by 95-98% and accelerates deployment timelines by 12-36 times compared to conventional methods. The technology ensures minimal environmental disturbance with a footprint of less than 500 m² and zero operational incidents, including no formation damage or groundwater contamination. This makes IRIS-X a transformative, sustainable, and economically viable platform for clean energy resource discovery.

Discover IRIS Technology

CRISPR-Engineered Therapeutic Cells for Precision Oncology The biomimetic nanohypertumor is an advanced therapeutic platform developed by Nanogeios that reprograms non-proliferative, CRISPR-edited tumor-mimetic cells into intelligent anti-cancer agents. These engineered cells simulate the tumor microenvironment while acting as controlled-release factories for anti-angiogenic proteins and immunomodulators. Delivered through dual-responsive nanocarriers—activated by tumor acidity (pH) and matrix metalloproteinase (MMP) activity—each nanohypertumor precisely targets malignant tissues, sparing healthy cells. Gene knockouts such as MYC and CDK4/6 ensure biological containment and non-replication. Coupled with our SpheroSim™ in silico modeling platform, this system achieves: High tumor specificity (>83%) Reduction in tumor vascularization Controlled molecular release profiles Minimal systemic toxicity The nanohypertumor platform bridges synthetic biology, nanotechnology, and clinical oncology—delivering programmable precision medicine with a high translational potential across multiple cancer types.